BPC-157 is a synthetic 15-amino-acid peptide derived from human gastric juice. Hundreds of animal studies document its ability to accelerate tissue repair, heal the gut lining, protect neurons, and reduce inflammation — making it one of the most researched peptides in the world.
Animal model research has documented BPC-157's effects across multiple biological systems. Here are the primary areas of study.
Shown in animal models to accelerate healing of gastric ulcers, IBD, and leaky gut by upregulating growth factors and promoting mucosal repair.
Promotes tendon-to-bone healing via VEGFR2 signaling and collagen synthesis. Widely studied for rotator cuff, ACL, and Achilles tendon injuries.
Preclinical data suggests BPC-157 crosses the blood-brain barrier and may protect dopaminergic neurons, with potential applications in TBI and Parkinson's.
Modulates the nitric oxide (NO) system and reduces pro-inflammatory cytokines, offering systemic anti-inflammatory effects without immunosuppression.
Stimulates new blood vessel formation (angiogenesis) at injury sites, accelerating nutrient delivery and tissue regeneration.
Animal studies show accelerated recovery from muscle tears and crush injuries. Often stacked with TB-500 for synergistic healing.
| Full Name | Body Protection Compound-157 |
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Amino Acids | 15 (pentadecapeptide) |
| Origin | Derived from human gastric juice protein |
| Primary Research Use | Tissue repair, gut healing, neuroprotection |
| Common Dosing Range | 200–500 mcg/day (research) |
| Administration Routes | Subcutaneous injection, intramuscular, oral |
| Half-Life | ~4 hours (estimated) |
| CAS Number | 137525-51-0 |
| Research Status | Preclinical (animal studies); Phase II trials pending |
Sources: PubMed, NIH, CAS Registry. All data is for educational purposes only.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protein found in human gastric juice. It consists of 15 amino acids and has been studied extensively in animal models for its tissue-healing, anti-inflammatory, and neuroprotective properties.
No. BPC-157 is not FDA-approved for human use. It is classified as a research chemical and is available for laboratory and research purposes only. Any use in humans is off-label and should only be considered under the supervision of a licensed medical provider.
BPC-157 works through multiple mechanisms: it upregulates VEGFR2 (vascular endothelial growth factor receptor 2) to promote angiogenesis, modulates the nitric oxide system to reduce inflammation, and activates growth hormone receptors to accelerate tissue repair. It also appears to interact with the dopaminergic and serotonergic systems in the brain.
In animal studies, BPC-157 is typically administered at 1–10 mcg/kg body weight. Extrapolating to human equivalents, this corresponds to roughly 200–500 mcg per day for a 70 kg adult. However, no established human dosing protocol exists, and these figures are for educational reference only.
Yes. Unlike many peptides, BPC-157 demonstrates notable oral bioavailability in animal models, particularly in its arginine salt form (BPC-157 arginine). Oral administration appears effective for gut-related conditions, while injection may be preferred for systemic or musculoskeletal applications.
BPC-157 is a 15-amino-acid peptide focused on gut healing, tendon repair, and neuroprotection. TB-500 (Thymosin Beta-4) is a 43-amino-acid peptide that promotes actin polymerization, systemic tissue repair, and angiogenesis. They are often stacked together (the 'Wolverine Stack') for synergistic healing effects.
In animal studies, BPC-157 has demonstrated a favorable safety profile with no significant toxicity at research doses. Reported side effects in anecdotal human use include nausea, dizziness, and injection site reactions. Long-term safety data in humans is not available.
PubMed and NIH databases contain hundreds of peer-reviewed studies on BPC-157. Key researchers include Dr. Predrag Sikiric at the University of Zagreb, whose lab has published the majority of BPC-157 animal studies. Search PubMed for 'BPC-157' or 'pentadecapeptide BPC 157' to access the primary literature.
Medical Disclaimer: All content on this page is for educational and informational purposes only. BPC-157 is not FDA-approved for human use and is classified as a research chemical. Nothing on this page constitutes medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before using any peptide or research compound.
We use cookies
We use cookies and similar technologies to improve your experience, analyze site traffic, and personalize content. By clicking "Accept," you consent to our use of cookies. Read our Privacy Policy for more information.